<i>In vivo</i> efficacy of oral OlPC against <i>L. major</i> in comparison with other antileishmanial drugs.

<p>BALB\c mice were infected with luciferase-labeled <i>L. major</i> promastigotes at the tail base. When lesions reached ∼50 mm² oral treatment with OlPC (40 mg/kg/day), miltefosine (40 mg/kg/day), fluconazole (160 mg/kg/day), or vehicle control (PBS) was initiated for 21 consecutive days (Day 0–Day 20). Amphotericin B was given intraperitoneally (IP) at 25 mg/kg/day for 10 days (Day 0–Day 9). Parasitemia (A) was measured in every group by <i>in vivo</i> imaging (IVIS) on a weekly basis until Day 28 post treatment start and expressed as number of total photons emitted per second. Ulcer sizes (B) were measured weekly using a calibrated digital caliper. Mean ± SEM is shown. * amphotericin B <i>P</i><0.05 compared to vehicle control. # amphotericin B and OlPC <i>P</i><0.05 compared to vehicle control.</p

Individual parasitemia and ulcer sizes on Day 19 post treatment start.

<p><i>L. major</i> infected BALB/c mice were treated with PBS vehicle control (oral), OlPC (oral, 40 mg/kg/day×21 days), miltefosine (oral, 40 mg/kg/day×21 days), fluconazole (oral, 160 mg/kg/day×21 days) and amphotericin B (IP, 25 mg/kg/day×10 days). Parasitemia (A and B) were measured on Day 19 using <i>in vivo</i> imaging technology (IVIS) and ulcer sizes were measured using a calibrated digital caliper (C). Means are shown as horizontal lines (B and C). * <i>P</i><0.05 compared to vehicle control.</p

Dose-response efficacy of OlPC in the mouse <i>L. major</i> lesion cure model (MLL).

<p>* <i>P</i><0.05 compared to vehicle control of the same route.</p><p>Dose-response efficacy of OlPC in the mouse <i>L. major</i> lesion cure model (MLL).</p

Sacrifices and found dead animals during comparative efficacy of OlPC in <i>L. major</i> infected BALB/c mice up to Day 35 post treatment start.

1<p>Last weight measurement compared to baseline weight for each mouse.</p>2<p>Linked to oral gavage.</p><p>Sacrifices and found dead animals during comparative efficacy of OlPC in <i>L. major</i> infected BALB/c mice up to Day 35 post treatment start.</p